All, n = 527 | Female, n = 276 (52.4%) | Male, n = 251 (47.6%) | P valuea | |
---|---|---|---|---|
Age | ||||
Mean | 70.5 | 70.6 | 70.4 | 0.399 |
Median | 71.4 | 72 | 70.9 | |
Range | 49.8 to 85.6 | 49.8 to 85.2 | 51.8 to 85.6 | |
Location | ||||
Colon | 323 (61.3) | 176 (63.8) | 147 (58.6) | 0.256 |
Rectum | 190 (36.1) | 92 (33.3) | 98 (39.0) | |
Multiple | 12 (2.3) | 7 (2.5) | 5 (2.0) | |
Unknown | 2 (0.4) | 1 (0.4) | 1 (0.4) | |
T Stage | ||||
1 | 46 (8.7) | 31 (11.2) | 15 (6.0) | 0.506 |
2 | 63 (12.0) | 30 (10.9) | 33 (13.1) | |
3 | 319 (60.5) | 159 (57.6) | 160 (63.7) | |
4 | 78 (14.8) | 42 (15.2) | 36 (14.3) | |
Unknown | 21 (4.0) | 39 (12.0) | 38 (12.7) | |
N stage | ||||
0 | 278 (52.8) | 144 (52.2) | 134 (53.4) | 0.494 |
1 | 118 (22.4) | 68 (24.6) | 50 (19.9) | |
2 | 85 (16.1) | 36 (13.0) | 49 (19.5) | |
Unknown | 46 (8.7) | 28 (10.1) | 18 (7.2) | |
M Stage | ||||
0 | 429 (81.4) | 226 (81.9) | 203 (80.9) | 0.513 |
1 | 90 (17.1) | 44 (15.9) | 46 (18.3) | |
Unknown | 8 (1.5) | 6 (2.2) | 2 (0.8) | |
Differentiation grade | ||||
High | 34 (6.5) | 19 (6.9) | 15 (6.0) | 0.438 |
Intermediate | 367 (69.6) | 185 (67.0) | 182 (72.5) | |
Low | 118 (22.4) | 67 (24.3) | 51 (20.3) | |
Unknown | 8 (1.5) | 5 (1.8) | 3 (1.2) | |
Vascular invasion | ||||
No | 150 (28.5) | 81 (29.3) | 69 (27.5) | 0.635 |
Yes | 156 (29.6) | 80 (29.0) | 76 (30.3) | |
Unknown | 222 (41.9) | 115 (41.7) | 106 (42.2) | |
Surgery | ||||
Acute | 46 (8.7) | 26 (9.4) | 20 (8.0) | 0.502 |
Elective | 454 (86.1) | 233 (84.4) | 221 (88.0) | |
Unknown | 27 (5.1) | 17 (6.2) | 10 (4.0) | |
Neodjuvant treatment | ||||
None | 414 (78.6) | 216 (83.4) | 198 (82.2) | 0.291 |
Short RT | 25 (4.7) | 10 (3.9) | 15 (6.2) | |
Long RT | 19 (3.6) | 8 (3.1) | 11 (4.6) | |
Chemotherapy + RT | 2 (0.4) | 2 (0.8) | 0 (0.0) | |
Chemotherapy | 2 (0.4) | 1 (0.4) | 1 (0.4) | |
Unknown | 65 (12.3) | 39 (14.1) | 16 (10.4) | |
Adjuvant treatment | ||||
No | 294 (55.8) | 149 (54.0.8) | 145 (57.8) | 0.584 |
FLV/Xeloda | 51 (9.7) | 25 (9.1) | 26 (10.4) | |
FLOX/XELOX | 19 (3.6) | 11 (4.0) | 8 (3.2) | |
Other | 5 (0.9) | 4 (1.4) | 1 (0.4) | |
Curative; M1* | 14 (2.7) | 6 (2.2) | 8 (3.2) | |
Palliative | 80 (15.2) | 39 (14.1) | 41 (16.3) | |
Unknown | 64 (12.1) | 42 (15.2) | 22 (8.8) | |
Follow-up (years) | ||||
Mean | 4.7 | 4,9 | 4.5 | 0.399 |
Median | 3.5 | 3.4 | 3.4 | |
Range | 0.0 to 17.7 | 0.0 to 17.7 | 0.0 to 16.6 | |
Vital status | ||||
Alive | 306 (58.1) | 169 (61.2) | 137 (54.6) | 0.113 |
Dead | 221 (41.9) | 107 (38.8) | 114 (45.4) | |
Dead from CRC | 182 (34.5) | 90 (32.6) | 92 (36.7) | 0.313 |
Follow-up (years); M1 patients | ||||
Mean | 1.5 | 1.3 | 1.6 | 0.129 |
Median | 1.1 | 0.8 | 1.2 | |
Range | 0.0 to 6.1 | 0.0 to 5.5 | 0.0 to 6.1 | |
Vital status; M1 patients | ||||
Alive | 12 (13.3) | 7 (15.9) | 5 (10.9) | 0.484 |
Dead | 78 (86.7) | 37 (84.1) | 41 (89.1) | |
Dead from CRC | 78 (86.7) | 37 (84.1) | 41 (89.1) | 0.484 |
Cyclin D1 fraction | ||||
0 to 1 | 105 (19.9) | 50 (18.1) | 55 (21.9) | 0.217 |
02 to 25 | 195 (37.0) | 100 (36.2) | 95 (37.8) | |
26 to 50 | 86 (16.3) | 48 (17.4) | 38 (15.1) | |
51 to 75 | 112 (21.3) | 64 (23.2) | 48 (19.1) | |
> 75 | 29 (5.5) | 14 (5.1) | 15 (6.0) | |
Cyclin D1 intensity | ||||
Negative | 105 (19.9) | 50 (18.1) | 55 (21.9) | 0.018 |
Weak | 181 (34.3) | 85 (30.8) | 96 (38.2) | |
Moderate | 176 (33.4) | 102 (37.0) | 74 (29.5) | |
Strong | 65 (12.3) | 39 (14.1) | 26 (10.4) |